- Home
- Companies
- canada ontario
- antigen presenting
Refine by
Antigen Presenting Suppliers Near Canada Ontario
38 companies found
based inActon, AUSTRALIA
Lipotek is a developer of targeted vaccine delivery and adjuvant technologies. There is an undeniable need for technological solutions for prophylactic and therapeutic vaccination against pathogens, cancer and other diseases that have limited or no ...
based inEdmonton, ALBERTA (CANADA)
Akshaya Bio Inc. (Akshaya) is a privately held development stage biotechnology company located in Edmonton, Alberta, Canada. Akshaya develops innovative therapeutics for infectious diseases and cancer. Akshaya's proprietary Chimigen® Platform ...
The Chimigen® Platform is a flexible platform vaccine technology designed to elicit both humoral and cellular immune responses in ...
based inSeattle, WASHINGTON (USA)
Universal Cells is a Seattle-based company that is producing engineered stem cell lines that can avoid rejection and be used in allogeneic cell therapy treatments for the people who need them. One Cell, Many Therapies. Universal Cells edits genes ...
The HLA Class II molecules DP, DQ and DR present peptides to CD4+ T cells and are composed of polymorphic alpha and beta chains. All Class II molecules are expressed from promoters that require the same set of transcription factors. Mutations in ...
based inEpalinges, SWITZERLAND
AC BioScience Ltd., a clinical-stage biotech company and a developer of immune modulating and angiogenic cancer therapies. AC BioScience LTD. is a Swiss biotech company, pioneering the development of novel therapies in immuno-oncology and tumor ...
Our patented Beta-carboline derivative (ACB1801) is an actin dynamic modulator which induces cellular F-actin network remodeling (tumor reversal); this in turn translates into immuno-competency that allows the immune system to recognize tumor cells ...
based inOslo, NORWAY
NEC OncoImmunity AS is an artificial intelligence (AI) driven biotech company offering proprietary machine-learning based software, which addresses the key knowledge gaps in the prediction of bona fide immunogenic antigens for personalized cancer ...
Recent advances in the field of immuno-oncology have established that mutated antigens (neoantigens), are viable targets of the immune system, potentially specific to each individual cancer patient. This plus many other breakthroughs in ...
based inGaithersburg, MARYLAND (USA)
NexImmune is a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIMâ„¢) technology. AIM nanoparticles act as synthetic dendritic cells to deliver ...
The injectable modality (AIM INJ) is an injectable pharmaceutical product of AIM nanoparticles decorated with antigen-specific peptides and co-stimulatory molecules appropriate for the disease being targeted. Based on specific size and ...
based inUtrecht, NETHERLANDS
At LAVA, we are focused on applying our expertise in gamma-delta T cell engagers. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor ...
Vγ9Vδ2 T cells belong to the first line of defense against cancer and have the potential to elicit deep and durable responses in the ...
based inWayne, PENNSYLVANIA (USA)
Sino Biological is committed to providing high-quality recombinant protein and antibody reagents and to being a one-stop technical services shop for life science researchers around the world. All of our products are independently developed and ...
FCAR, also called FcαRI or CD89, is a type I transmembrane receptor for Fc region of IgA which is the most abundant immunoglobulin in mucosal areas but is only the second most common antibody isotype in serum. This receptor is present on the ...
based inCambridge, MASSACHUSETTS (USA)
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer ...
Immunotherapeutic cancer vaccines have generated a lot of interest from oncologists since it was discovered that immune activation can lead to a specific antitumor response.1 However, despite initial progress, most cancer vaccines have failed to ...
based inRehovot, ISRAEL
ProSpec is an evolving biotech company providing highly purified proteins worldwide which serve the research community with cytokine-related products for cancer, apoptosis, development, endocrinology, immunology, neuroscience, proteases, and stem ...
4 1BBL Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 184 amino acids and having a molecular mass of 19.5kDa. The 4 1BBL is purified by proprietary chromatographic techniques. ...
based inSan Mateo de Gállego Zaragoza, SPAIN
CerTest Biotec, S.L. is an independent biotechnology company devoted to the development and manufacturing of IVD diagnostic products in human clinical field. An innovative technology-based company whose success lies in its human capital, highly ...
CerTest Legionella one step card test is a coloured chromatographic immunoassay for the qualitative detection of Legionella pneumophila serogroup 1 in human urine samples. CerTest Legionella card test offers a highly sensitive and simple screening ...
based inCarlsbad, CALIFORNIA (USA)
Founded in 1996, IVD Research, Inc. is privately held by Dave Lambillotte, Ann Marie Martin and Christopher Lambillotte. Our tight-knit group of dedicated professionals works well as a team, each bringing their own unique experiences and education ...
Giardiasis, caused by the single-celled Giardia lambliaparasite, is the most common parasitic disease in the United States. As many as 100 million mild infections and 1 million severe infections are reported ...
based inWürzburg, GERMANY
Toleris Biotherapeutics GmbH is a biotechnology company based in Würzburg, Germany. The company specializes in the development of innovative biotherapeutic solutions aiming to advance the field of medicine through cutting-edge scientific research. ...
AIM Bio has developed a platform of Autoimmunity Modifying Biologicals (AIM Biologicals) that uses soluble, near-physiological proteins to induce selective, antigen-specific immune tolerance. These proteins mimic a natural process ...
based inHouston, TEXAS (USA)
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) is a public biopharmaceutical company based in the Houston, TX area that is developing GP2, a novel peptide immunotherapy, and has commenced a Phase III clinical trial, called Flamingo-01. GP2 is derived ...
Cancer Immunotherapies are a New Method of Cancer Treatment. Among the more established treatment options, such as surgery, chemotherapy, targeted therapy, and radiation therapy, cancer immunotherapy is a rapidly emerging and important field. It ...
based inMenlo Park, CALIFORNIA (USA)
Adicet is a biotechnology company engaged in the development of first-in-class off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet has developed a proprietary cell platform process to activate, engineer and ...
Gamma delta T cells represent a new generation of universal cell therapy. The current engineered autologous alpha beta T cell products have shown significant efficacy in hematological malignancies; however comparable efficacy in solid tumors is yet ...
based inPalo Alto, CALIFORNIA (USA)
Immune-Onc is a clinical-stage company developing a novel class of myeloid checkpoint inhibitors. We believe myeloid checkpoints are the next frontier of immunotherapy for cancer. In collaboration with scientists, our research team is among the ...
Immune-Onc’s lead program is IO-202, an antagonist antibody targeting the myeloid checkpoint LILRB4 (also known as ILT3). Immune-Onc has a Phase I trial underway to evaluate IO-202 as a potential treatment for acute myeloid leukemia (AML) and ...
based inLangenfeld, GERMANY
ARTES Biotechnology is a globally working, well established and reliable technology provider for recombinant protein production. We develop microbial cell lines and processes for vaccines, biopharmaceuticals, biosimilars and enzymes and offer ...
based inLoveland, COLORADO (USA)
Through innovation, invention, and strategic partnerships with worldwide leaders in diagnostics and treatments, Heska provides the benefits of latest generation technologies to pet healthcare providers. Heska’s range of complete blood diagnostic ...
The safest long term allergy treatment solution for canine, feline or equine ...
based inSuwon-si, SOUTH KOREA
SD BIOSENSOR is a professional in-vitro diagnostics company with aims of contributing to higher life quality by diagnosing illnesses accurately and quickly. SD BIOSENSOR is researching and developing quick diagnostics, immunodiagnostics, molecular ...
STANDARD Q COVID-19 Ag Home Test is a rapid chromatographic immunoassay for the qualitative detection of SARS-CoV-2 nucleocapsid antigen present in human nasal ...
based inSeoul, SOUTH KOREA
GI Innovation is a bio-venture company that researches and develops innovative protein new drugs through well-structured translational research. The primary research and development for GI Innovation is immuno-oncology drug and allergy disease and ...
Promotes the generation of cancer-specific effector T cell (Teff) in lymph nodes, and induces the activation and proliferation of tumor-infiltrating Teff and NK cells. Controls the immuno-suppressive function of regulatory T cells (Tregs) in tumor ...